http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View More Recent Stories
-
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2015 Leerink Global Healthcare Conference
-
Sucampo Appoints Andrew Smith, FCMA, CGMA as CFO
-
Robert J. Spiegel, M.D., FACP Joins Sucampo's Board of Directors
-
Sucampo Announces Acceptance of New Drug Submission for AMITIZA(R) (lubiprostone) by Health Canada
-
Sucampo Appoints John H. Johnson to Board of Directors
-
Sucampo Files Patent Infringement Lawsuit Against Dr. Reddy's
-
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the Stifel 2014 Healthcare Conference
-
Sucampo Announces Third Quarter 2014 Financial Results
-
Sucampo Pharmaceuticals, Inc. Announces Third Quarter 2014 Earnings Call
-
Sucampo Solidifies Leadership Team With Additions of CSO and Heads of Business Development, Regulatory Affairs
-
Takeda and Sucampo Enter Into Global Licensing Agreement for AMITIZA(R) (lubiprostone)
-
Sucampo Announces Extension of AMITIZA(R) (lubiprostone) License and Collaboration Agreement With Takeda
-
Clinical Data for AMITIZA(R) Lubiprostone to be Presented at the American College of Gastroenterology 2014 Annual Scientific Meeting
-
Sucampo Announces Settlement Agreement That Resolves Patent Litigation in U.S. Related to AMITIZA
-
Sucampo Announces Departure of Chief Financial Officer
-
Sucampo and Takeda Launch Direct-to-Consumer Advertising Campaign for AMITIZA(R) (lubiprostone) for Chronic Idiopathic Constipation
-
Sucampo Announces New Exclusive Global Manufacturing and Supply Agreement for Lubiprostone
-
Sucampo Reports Second Quarter 2014 Financial Results and Corporate Update
-
Sucampo Announces Publication of NICE Recommendation for AMITIZA(R) (Lubiprostone)
-
Sucampo Pharmaceuticals, Inc. Announces Second Quarter 2014 Financial Results and Corporate Update Teleconference and Webcast on August 5
-
Swissmedic Approves AMITIZA(R) (Lubiprostone) for the Treatment of Opioid-Induced Constipation
-
Sucampo Issues Statement Regarding Anesthetic and Analgesic Drug Products Advisory Committee Meeting's Vote
-
Sucampo Announces Webcast of Its Presentation at 2014 Jefferies Global Healthcare Conference
-
Sucampo Announces Webcast of Its Presentation at the 2014 UBS Global Healthcare Conference
-
Sucampo Pharmaceuticals, Inc., Reports First Quarter 2014 Financial and Operating Results
-
Sucampo Announces Clinical Data on Lubiprostone to be Presented at Two Upcoming Scientific Conferences
-
Sucampo Pharmaceuticals Announces First Quarter 2014 Results and Operating Highlights Teleconference and Webcast
-
Preclinical Data for Lubiprostone and Unoprostone Isopropyl to be Presented at Experimental Biology Conference 2014
-
Sucampo Co-Founder and Chairman Emeritus, Dr. Ryuji Ueno, to Receive Visionary Award From the Foundation Fighting Blindness
-
Sucampo and Takeda Announce Update on Liquid Formulation Program for AMITIZA(R) (lubiprostone)
-
Sucampo Receives Notice that Second Indication for AMITIZA for Opioid-Induced Constipation Is Not Approved by Medicines and Healthcare Products Regulatory Agency in U.K.
-
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2014 ROTH Conference
-
Sucampo and National Cherry Blossom Festival Announce Sucampo as Host and 'Step Into Spring' Program Sponsor for 2014
-
Sucampo Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2013 Financial and Operating Results
-
Sucampo Names Peter Greenleaf Chief Executive Officer
-
All Physicians in Switzerland Are Now Able to Prescribe Sucampo's AMITIZA(R) for Chronic Idiopathic Constipation
-
Sucampo Reports Results from Phase 2a Study of Intravenous Ion Channel Activator for Lumbar Spinal Stenosis
-
Sucampo and Takeda Initiate Global Pivotal Phase 3 Program of Lubiprostone in Pediatric Functional Constipation

